Viking Therapeutics has launched phase 3 trials for its oral obesity drug. The program now moves into late-stage testing, creating a clinical milestone for the company’s obesity-drug pipeline.
Viking Therapeutics has begun phase 3 trials for an oral obesity drug, moving the candidate into the late-stage portion of its development program.
The launch follows earlier-stage work on the treatment and marks a new clinical-development step for Viking. Phase 3 testing is intended to generate the larger-scale evidence used in later regulatory decisions.
The program connects Viking to the growing obesity-drug market through an oral treatment rather than an injectable product. Its eventual commercial significance will depend on the trial results and the drug’s path through regulatory review.
The outcome remains dependent on clinical data from the new trials. Key questions include the treatment’s efficacy, safety, tolerability and ability to support a future application.
The next milestones are the trial readouts and any subsequent regulatory filing or decision tied to the oral obesity drug.
Our take
1 / 6
Our read · Oct 14
Viking Therapeutics (VKTX) launched phase 3 trials for its oral obesity drug.
Why
The phase 3 launch advances Viking’s oral obesity program into the clinical stage that can support a future regulatory submission, but the value of the program still turns on efficacy and safety results. No dated readout is established, so the setup does not support a conviction lean; the next material test is the trial data.
What could change this view
Unfavorable efficacy, safety or tolerability results could halt the program or delay regulatory progress.
▲ The case it holds
Phase 3 enrollment and successful results would give Viking a later-stage oral obesity asset with a potential route toward regulatory review.
▼ The case it breaks
The clinical program remains unproven at phase 3, and weak efficacy or safety data would undermine the oral obesity-drug opportunity.
Prices: 1D EOD · OCT 14 CLOSE, licensed end-of-day data.
Source: Investing.com · Published here WED, OCT 14 · 7:12 AM ET · the only report in this record · How this is decided →
Photo: Stock photo · Maurício Mascaro
Kept as written · your side, if you take one, is graded privately against licensed closes after 10 trading days · reaction = the first close after a story against the close before it · nothing here is advice · How the Wire is made →
Photo credit ↓